Impact of Door to Needle Time of Antibiotics Administration on Outcome in Cancer Patients with Febrile Neutropenia
Main Article Content
Abstract
Objective: To determine the outcome of the door-to-needle time of antibiotics in cancer patients with febrile neutropenia.
Methodology: It was a prospective cross-sectional study conducted at the emergency department of Shaukat Khanum Memorial Hospital Peshawar from April 2023 to December 2023. All the patients presenting to the emergency room with fever and a history of diagnosed malignancy, who received chemotherapy in the past 14 days and confirmed febrile neutropenia (fever>100 F and absolute neutrophil count of <500 cells/microliter) were included. Patients younger than 18 years of age were excluded. Data was analyzed through SPSS 24.0. A P value less than 0.05 was considered significant.
Results: A total of 79 patients fulfilled the eligibility criteria. Most were males, i.e., 52 (65.8%). The mean age of patients was 51.71 ±9.8 years. The most common malignancy was lymphoma (25.3%), followed by sarcoma (12.6%) and breast cancer (11.3%). The mean duration of stay was 4.2±3.2 days. The mean MASCC score was 17.6 ±1.76. Sixty-two (78.5%) patients received antibiotics within one hour of arrival at the emergency room. Only two patients died during a hospital stay. A significantly increased number of admissions to the intensive care unit, length of hospital stay, and escalating antibiotic use were observed in patients who did not receive antibiotics within one hour of arrival compared to the other group. No statistically significant difference was noted in-hospital deaths among both groups.
Conclusion: Timely antibiotics significantly lowered intensive care admissions and length of hospital stay. However, our study did not find its impact on in-hospital deaths.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Rasmy A, Amal A, Fotih S, Selwi,W. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res 2016;5(3):273-8.
Pettit N, Boadu D, Bischof JJ. Emergency department management of chemotherapy-related febrile neutropenia: An opportunity to improve care. Am J Emerg Med 2021;50:5-9.
Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 2014;14:162
Ali N, Baqir M, Hamid A, Khurshid M. Febrile neutropenia: median door-to-needle time - results of an initial audit. Hematology 2015;20(1):26-30.
Peyrony O, Gerlier C, Barla I, Ellouze S, Legay L, Azoulay E, et al. Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department. Plos one 2020;15(2).
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, et al. Risk and consequences of chemotherapy-Induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 2015;11(1):47-54.
Aagaard T, Reekie J, Jørgensen M, A Roen, G Daugaard, L Specht, et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med 2020;9(9):3033-42.
Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer 2020;28(3):1369-83.
Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer 2013;60(8):1299-306.